Skip to Content
Merck
CN

Key Documents

View All Documentation

SML2983

Vandetanib

≥98% (HPLC)

Synonym(s):

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, ZD6474

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H24BrFN4O2
CAS Number:
443913-73-3
Molecular Weight:
475.35
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD07772346
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

Fc1c(ccc(c1)Br)Nc2ncnc3c2cc(c(c3)OCC4CCN(CC4)C)OC

InChI

1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

InChI key

UHTHHESEBZOYNR-UHFFFAOYSA-N

Biochem/physiol Actions

Orally active, selective inhibitor of VEGF receptor kinase activity; also inhibits EGFR and RET tyrosine kinases
Vandetanib is an orally active and potent inhibitor of vascular endothelial growth factor receptor receptor 2 (VEGFR2) kinase activity that is used to treat medullary thyroid cancer. Vandetanib also inhibits epidermal growth factor receptor (EGFR), and RET tyrosine kinases.

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2

target_organs

Gastrointestinal tract

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000420937
0000420938
0000420938
0000420937
0000369194

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ole Vincent Ancker et al.
International journal of molecular sciences, 21(1) (2019-12-22)
Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) therapy. Unfortunately, some thyroid cancer types are resistant to surgical and RAI therapy. Multikinase inhibitors (MKIs)
Laurent F Hennequin et al.
Journal of medicinal chemistry, 45(6), 1300-1312 (2002-03-08)
We have previously shown that 4-anilinoquinazolines can be potent inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt-1 and KDR) tyrosine kinase activity. A novel subseries of 4-anilinoquinazolines that possess basic side chains at the C-7 position of the quinazoline
Francesca Carlomagno et al.
Cancer research, 62(24), 7284-7290 (2002-12-25)
RET/papillary thyroid carcinoma (PTC) oncogenes, generated by recombination of the tyrosine kinase-encoding domain of RET with different heterologous genes, are prevalent in papillary carcinomas of the thyroid. Point mutations of RET cause multiple endocrine neoplasia type 2 (MEN2) familial cancer

Global Trade Item Number

SKUGTIN
SML2983-5MG04065265405959
SML2983-25MG04065265405942